Loading...
Market
Which major recognition will OncoGAN receive by October 2025?
2
Resolution / Starting Odds
Nobel Prize in Medicine • 25%
Breakthrough Prize in Life Sciences • 25%
No major awards • 25%
Other recognition • 25%
Announcements from scientific award bodies or industry organizations
Story
New AI Pipeline OncoGAN Generates Synthetic Cancer Genomes, Addressing Privacy Concerns
Oct 21, 2024, 05:57 AM
A novel AI-based pipeline called OncoGAN has been introduced to generate realistic synthetic cancer genomes using generative adversarial networks (GANs) and tabular variational autoencoders (VAEs). This approach addresses the limitations of real patient genomic data due to privacy concerns. The development of OncoGAN aims to facilitate research in precision oncology by providing high-quality synthetic genomic data for algorithm development and benchmarking.
View original story
Similar markets
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Nobel Prize • 25%
Lasker Award • 25%
Breakthrough Prize • 25%
No award • 25%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Best AI Startup • 25%
Best Architectural Innovation • 25%
Best Use of AI in Design • 25%
Other • 25%
Successful Phase I trial • 25%
FDA Fast Track designation • 25%
Publication of promising preclinical results • 25%
No major milestone achieved • 25%
AWS • 25%
Deloitte • 25%
Microsoft • 25%
Nvidia • 25%
New drug approval • 25%
Major clinical trial success • 25%
New treatment guidelines • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Best New Drug • 25%
Innovation in Oncology • 25%
No major award • 25%
Other • 25%
Phase II trial completion • 25%
Phase III trial commencement • 25%
FDA approval • 25%
None of the above • 25%